Anaptysbio (ANAB) Non Operating Income (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Non Operating Income data on file, last reported at -$18.2 million in Q1 2026.

• Quarterly Non Operating Income fell 55.01% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.4 million (down 67.35% YoY) and the FY2025 annual result came in at -$61.0 million, down 101.34% from the prior year.
• Non Operating Income slipped to -$18.2 million in Q1 2026, from -$17.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $424000.0 in Q3 2023 to a low of -$19.6 million in Q3 2025.
• A 5-year average of -$7.2 million and a median of -$4.8 million in 2022 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income soared 110.96% — and 2024, when it plunged 15050.0%.
• Tracing ANAB's Non Operating Income over 5 years: stood at -$416000.0 in 2022, then surged by 80.77% to -$80000.0 in 2023, then sank by 15050.0% to -$12.1 million in 2024, then slumped by 41.96% to -$17.2 million in 2025, then slipped by 5.82% to -$18.2 million in 2026.
• The last three Non Operating Income figures came in at -$18.2 million (Q1 2026), -$17.2 million (Q4 2025), and -$19.6 million (Q3 2025), per Business Quant data.